Consolidative Radiotherapy in the Treatment of Primary Mediastinal Large B-Cell Lymphoma
Vol. 71 No. 1 (2025), ORIGINAL ARTICLES. C. CLINICAL RESEARCH
Vol. 71 No. 1 (2025)

Consolidative Radiotherapy in the Treatment of Primary Mediastinal Large B-Cell Lymphoma

ORIGINAL ARTICLES. C. CLINICAL RESEARCH
https://doi.org/10.37469/0507-3758-2025-71-1-OF-2215
Published 28.02.2025
Leonid A. Kramynin
NMRC of Oncology named after N.N.Petrov of MoH of Russia
https://orcid.org/0000-0003-4542-8353
Larisa V. Filatova
NMRC of Oncology named after N.N.Petrov of MoH of Russia
https://orcid.org/0000-0002-0728-4582
Margarita S. Motalkina
NMRC of Oncology named after N.N.Petrov of MoH of Russia
https://orcid.org/0000-0002-6711-8017
Ilya S. Zyuzgin
NMRC of Oncology named after N.N.Petrov of MoH of Russia
https://orcid.org/0000-0001-9597-4593
Yuliya A. Nikulina
NMRC of Oncology named after N.N.Petrov of MoH of Russia
https://orcid.org/0009-0005-5458-6865
Svetlana S. Elkhova
NMRC of Oncology named after N.N.Petrov of MoH of Russia
https://orcid.org/0000-0002-1691-0549
Irina V. Ishmatova
NMRC of Oncology named after N.N.Petrov of MoH of Russia
https://orcid.org/0009-0004-2898-9823
Anna A. Zverkova
NMRC of Oncology named after N.N.Petrov of MoH of Russia
https://orcid.org/0009-0008-8457-0487
Stanislav A. Volchyonkov
NMRC of Oncology named after N.N.Petrov of MoH of Russia
https://orcid.org/0000-0002-2463-2024
Evgeniya V. Dobrovolskaya
NMRC of Oncology named after N.N.Petrov of MoH of Russia
https://orcid.org/0000-0002-4775-2184
Nikita S. Kolupaev
NMRC of Oncology named after N.N.Petrov of MoH of Russi
https://orcid.org/0000-0002-0291-4928
Anastasia G. Kolgotina
NMRC of Oncology named after N.N.Petrov of MoH of Russia
https://orcid.org/0009-0001-2174-9083
Alina O. Eliseeva
Saint Petersburg Pediatric University
https://orcid.org/0009-0009-4176-6444
Tatiana Yu. Semiglazova
NMRC of Oncology named after N.N.Petrov of MoH of Russia
https://orcid.org/0000-0002-4305-6691
##article.numberofdownloads## 16
##article.numberofviews## 89
pdf (Русский)

Keywords

primary mediastinal large B-cell lymphoma
first-line therapy
DA-EPOCH-R
consolidative radiotherapy

How to Cite

Kramynin, L. A., Filatova, L. V., Motalkina, M. S., Zyuzgin, I. S., Nikulina, Y. A., Elkhova, S. S., Ishmatova, I. V., Zverkova, A. A., Volchyonkov, S. A., Dobrovolskaya, E. V., Kolupaev, N. S., Kolgotina, A. G., Eliseeva, A. O., & Semiglazova, T. Y. (2025). Consolidative Radiotherapy in the Treatment of Primary Mediastinal Large B-Cell Lymphoma. Voprosy Onkologii, 71(1), OF–2215. https://doi.org/10.37469/0507-3758-2025-71-1-OF-2215
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

Introduction. The first line of therapy for primary mediastinal large B-cell lymphoma is controversial. The most uncertain issue is the appointment of radiation therapy after the medicinal stage of treatment. According to the results of several retrospective studies, consolidative radiotherapy can be abandoned in patients with a complete metabolic response and a partial metabolic histologically negative response.

Aim. To compare the long-term results of treatment in patients with a complete metabolic response and a partial metabolic histologically negative response after the medicinal stage of treatment, depending on the use of consolidative radiotherapy.

Materials and Methods. We retrospectively analyzed the long-term treatment results (progression-free survival and overall survival) of 63 patients, 31 patients received only 6 courses of DA-EPOCH-R chemotherapy and 32 patients additionally received consolidative radiotherapy after the medicinal stage of treatment.

Results. Progression-free survival was 93.6 % in the observation arm and 93.8 % in the radiotherapy arm, HR 0.55 (95 % CI 0.07-4.21). The overall survival was 96.8 % in the observation arm and 96.9 % in the radiotherapy arm, HR 0.98 (95 % CI 0.06-15.74).

Conclusion. These results demonstrate the absence of a positive effect of radiotherapy on long-term treatment outcomes in patients with a complete metabolic response and a partial metabolic histological negative response after immunochemotherapy, and allow the omission of consolidative radiotherapy without loss of treatment efficacy.

https://doi.org/10.37469/0507-3758-2025-71-1-OF-2215
##article.numberofdownloads## 16
##article.numberofviews## 89
pdf (Русский)

References

Martelli M., Ferreri A., Di Rocco A., et al. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol. 2017; 113: 318-327.-DOI: https://doi.org/10.1016/j.critrevonc.2017.01.009.

NCCN Guidelines Version 3.2024 Primary Mediastinal Large B-Cell Lymphoma. National Comprehensive Cancer Network.-URL: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.

Общероссийский национальный союз «Ассоциация онкологов России». Региональная общественная организация «Общество онкогематологов». Некоммерческое партнерство содействия развитию гематологии и трансплантологии костного мозга «Национальное гематологическое общество». Региональная общественная организация Национальное общество детских гематологов и онкологов. Клинические рекомендации. Агрессивные нефолликулярные лимфомы – диффузная крупноклеточная В-клеточная лимфома, первичная медиастинальная В-клеточная лимфома, лимфома Беркитта. 2020.-URL: https://oncology-association.ru/wp-content/uploads/2020/09/agressivnye_nefollikuljarnye_limfomy.pdf. [All-Russian National Union «Association of Oncologists of Russia». Regional public organization "Society of Oncogematologists". Non-profit Partnership for the Promotion of Hematology and Bone Marrow Transplantation "National Hematology Society". The regional public organization is the National Society of Pediatric Hematologists and Oncologists. Clinical recommendations. Aggressive non–follicular lymphomas are diffuse large-cell B-cell lymphoma, primary mediastinal B-cell lymphoma, Burkitt's lymphoma. 2020.-URL: https://oncology-association.ru/wp-content/uploads/2020/09/agressivnye_nefollikuljarnye_limfomy.pdf. (In Rus)].

Hoppe B.S., Advani R., Milgrom S.A., et al. Primary mediastinal B cell lymphoma in the positron‐emission tomography era executive summary of the American Radium Society appropriate use criteria. Int J Radiat Oncol Biol Phys. 2021; 111(1): 36-44.-DOI: https://doi.org/10.1016/j.ijrobp.2021.03.035.

Chan E.H.L., Koh L.P., Lee J., et al. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma. Cancer Med. 2019; 8(10): 4626-4632.-DOI: https://doi.org/10.1002/cam4.2347.

Messmer M., Tsai H.L., Varadhan R., et al. R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma. Leuk Lymphoma. 2019; 60(5): 1261-1265.-DOI: https://doi.org/10.1080/10428194.2018.1519812.

Held G., Thurner L., Poeschel V., et al. Radiation and dose-densification of R-CHOP in primary mediastinal b-cell lymphoma: subgroup analysis of the UNFOLDER trial. Hemasphere. 2023; 7(7): e917.-DOI: https://doi.org/10.1097/HS9.0000000000000917.

Артемьева А.С., Семиглазова Т.Ю., Франк Г.А. В-клеточные лимфомы средостения из крупных клеток. Вопросы онкологии. 2015; 61(2): 280-288.-EDN TRUXHN. [Artemieva A.S., Semiglazova T.Yu., Frank G.A. Mediastinal B-cell lymphomas from large cells. Voprosy Onkologii = Problems in Oncology. 2015; 61(2): 280-288.-EDN TRUXHN. (In Rus)].

Artemieva A.S., Frank G.A. Primary mediastinal large B-cell lymphoma: immunohistochemical features and differential diagnostics. Virchows Arch. 2013; 463(2): 136.-EDN XCVMSD.

Cheson B.D., Fisher R.I., Barrington S.F., et al Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27): 3059-68.-DOI: https://doi.org/10.1200/JCO.2013.54.8800.

Abou-Elella A.A., Weisenburger D.D., Vose J.M., et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. J Clin Oncol. 1999; 17(3): 784-784.-DOI: https://doi.org/10.1200/jco.1999.17.3.784.

Kuruvilla J., Pintilie M., Tsang R., et al. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma. 2008; 49(7): 1329-36.-DOI: https://doi.org/10.1080/10428190802108870.

Savage K.J., Al-Rajhi N., Voss N., et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006; 17(1): 123-30.-DOI: https://doi.org/10.1093/annonc/mdj030.

Dunleavy K., Pittaluga S., Maeda L.S., et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013; 368(15): 1408-16.-DOI: https://doi.org/10.1056/nejmoa1214561.

Shah N.N., Szabo A., Huntington S.F., et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018; 180(4): 534-44.-DOI: https://doi.org/10.1111/bjh.15051.

Camus V., Rossi C., Sesques P., et al. Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study. Blood Adv. 2021; 5(19): 3862-3872.-DOI: https://doi.org/10.1182/bloodadvances.2021004778.

Moskowitz C.H., Hamlin P.A., Maragulia J., et al. Sequential dose-dense RCHOP followed by ICE consolidation (MSKCC protocol 01-142) without radiotherapy for patients with primary mediastinal large B cell lymphoma. Blood. 2010; 116(21): 420-420.-DOI: https://doi.org/10.1182/blood.v116.21.420.420.

Goldschmidt N., Kleinstern G., Orevi M., et al. Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy. Cancer Chemother Pharmacol. 2016; 77(5): 1053-60.-DOI: https://doi.org/10.1007/s00280-016-3024-8.

Morgenstern Y., Aumann S., Goldschmidt N., et al. Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study. Cancer Med. 2021; 10(24): 8866-8875.-DOI: https://doi.org/10.1002/cam4.4387.

Giulino-Roth L., O'Donohue T., Chen Z., et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol. 2017; 179(5): 739-747.-DOI: https://doi.org/10.1111/bjh.14951.

Pinnix C.C., Ng A.K., Dabaja B.S., et al. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018; 2(11): 1334-1343.-DOI: https://doi.org/10.1182/bloodadvances.2018017681.

Melani C., Advani R., Roschewski M., et al. End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. Haematologica. 2018; 103(8): 1337-1344.-DOI: https://doi.org/10.3324/haematol.2018.192492.

Vassilakopoulos T.P., Piperidou A., Mellios Z., et al. PET for response assessment to R-da-EPOCH in primary mediastinal large B-cell lymphoma: who is worthy to be irradiated? Hemasphere. 2023; 7(11): e965.-DOI: https://doi.org/10.1097/HS9.0000000000000965.

Martelli M., Ceriani L., Ciccone G., et al. Omission of radiotherapy in primary mediastinal B-cell lymphoma: IELSG37 trial results. J Clin Oncol. 2024: JCO2401373.-DOI: https://doi.org/10.1200/JCO-24-01373.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2025

Most read articles by the same author(s)